Mavorixafor
Mavorixafor is a once-daily tablet that blocks CXCR4, a receptor that traps white cells in the bone marrow. It is approved for the rare immunodeficiency WHIM syndrome and is being tested in Waldenström macroglobulinaemia, where CXCR4 mutations blunt the response to ibrutinib.
Overview
Mavorixafor is X4 Pharmaceuticals' oral CXCR4 antagonist. The FDA approved it in April 2024 for WHIM syndrome, a rare primary immunodeficiency caused by gain-of-function CXCR4 mutations, where it raises neutrophil and lymphocyte counts and reduces infections. The same mutations occur somatically in 30 to 40 percent of Waldenström macroglobulinaemia, where they lower and slow responses to BTK inhibitors.
A phase 1b trial combined mavorixafor with ibrutinib in CXCR4-mutant Waldenström macroglobulinaemia and reported deeper responses than expected from ibrutinib alone in this subgroup. The Waldenström page names the trials as one answer to the open problem of CXCR4-mutant disease.
Blocks the chemokine receptor CXCR4, releasing neutrophils and lymphocytes from the marrow; in Waldenström macroglobulinaemia, activating CXCR4 mutations in about a third of patients cause resistance to BTK inhibitors, which the antagonist is meant to overcome. Connects to CXCR4.
1.Mavorixafor slips into a pocket on CXCR4.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2024 | WHIM syndrome (warts, hypogammaglobulinaemia, infections and myelokathexis) in patients aged 12 and over |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Mavorixafor" OR ABSTRACT:"Mavorixafor" OR TITLE:"Xolremdi" OR ABSTRACT:"Xolremdi" OR TITLE:"X4P-001" OR ABSTRACT:"X4P-001" OR TITLE:"AMD-070" OR ABSTRACT:"AMD-070") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mavorixafor, not a curated reading list.
Similar pages
not linked directly; found by shared links- TermMYD88 L265P and CXCR4 mutations
Shares CXCR4, Waldenström macroglobulinaemia, Ibrutinib.
- TargetHCK kinase
Shares Waldenström macroglobulinaemia, Ibrutinib.
- PathwayB-cell receptor / BTK signalling (to NF-κB)
Shares Waldenström macroglobulinaemia, Ibrutinib.
- TermBTK C481S, PLCG2 and BCL2 G101V resistance mutations
Shares Waldenström macroglobulinaemia, Ibrutinib.